The NICHE-2 study offered neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer patients, resulting in a major pathologic response in 95% of patients and 67% pCR. In discussion with the lead author, Dr. Myriam Chalabi – Medical Oncologist at the Netherlands Cancer Institute.